Technical Analysis for CARA - Cara Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Weak + Overbought | Other | -7.46% | |
| Gapped Up | Strength | -7.46% | |
| Overbought Stochastic | Strength | -7.46% | |
| Up 3 Days in a Row | Strength | -7.46% | |
| Up 4 Days in a Row | Strength | -7.46% | |
| Up 5 Days in a Row | Strength | -7.46% | |
| Pocket Pivot | Bullish Swing Setup | -7.20% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 7 hours ago |
| Down 10% | about 9 hours ago |
| Down 1 ATR | about 9 hours ago |
| Fell Below 20 DMA | about 10 hours ago |
| 10 DMA Support | about 10 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Clinical Trial Chronic Pain Amines Acute And Chronic Pain Piperidines Mesoblast
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Clinical Trial Chronic Pain Amines Acute And Chronic Pain Piperidines Mesoblast
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.665 |
| 52 Week Low | 0.5 |
| Average Volume | 497,547 |
| 200-Day Moving Average | 1.30 |
| 50-Day Moving Average | 0.83 |
| 20-Day Moving Average | 0.74 |
| 10-Day Moving Average | 0.75 |
| Average True Range | 0.07 |
| RSI (14) | 45.65 |
| ADX | 19.88 |
| +DI | 16.77 |
| -DI | 23.07 |
| Chandelier Exit (Long, 3 ATRs) | 0.65 |
| Chandelier Exit (Short, 3 ATRs) | 0.84 |
| Upper Bollinger Bands | 0.82 |
| Lower Bollinger Band | 0.65 |
| Percent B (%b) | 0.49 |
| BandWidth | 22.69 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.0092 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.87 | ||||
| Resistance 3 (R3) | 0.88 | 0.84 | 0.85 | ||
| Resistance 2 (R2) | 0.84 | 0.80 | 0.83 | 0.84 | |
| Resistance 1 (R1) | 0.79 | 0.78 | 0.77 | 0.78 | 0.83 |
| Pivot Point | 0.75 | 0.75 | 0.74 | 0.74 | 0.75 |
| Support 1 (S1) | 0.70 | 0.71 | 0.68 | 0.69 | 0.64 |
| Support 2 (S2) | 0.66 | 0.69 | 0.65 | 0.63 | |
| Support 3 (S3) | 0.61 | 0.66 | 0.62 | ||
| Support 4 (S4) | 0.60 |
